SCINAI IMMUNOTHERAPEUTICS LT

Scinai Immunotherapeutics: 24‑hour snapshot shows modest gains amid low liquidity, but strong pre‑clinical data and partnership prospects hint at upside potential.

SCNI shares tumble 10% to $0.64, below its 200‑day average—find out what’s driving the steep drop in this biopharma stock’s latest performance.

Scinai Immunotherapeutics shares drop 55% as biotech sector slumps – explore why the I&I pipeline faces a tough correction and what investors need to watch.

Scinai Immunotherapeutics’ shares tumble 55% as investors question its biopharma pipeline and lack of partnership, putting the company’s future in doubt.